Recipharm expands Swedish facility; FDA warns Chinese OTC maker; DSM, Indoco ink pact;

> Sweden's Recipharm will expand capacity of its analytical services and stability studies at its facility in Solna, Sweden. Release

> The FDA has warned Shanghai Huhui Daily Use Chemical Products that its products may be refused entry into the U.S. until it fixes a host of problems inspectors found at its manufacturing plant in Shanghai. Warning Letter

> India-based packaging company ACG Worldwide is plunking down about $71 million in the phased construction of a new manufacturing plant at Pithampur, Indore, India. Item

> DSM Pharmaceuticals has struck a deal with Indian API maker Indoco Remedies to sell 8 of its active pharmaceutical ingredients. Item

And Finally... With the patent cliff ending for branded drugmakers, the fiscal precipice now looms for generics makers. Story

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.